UBS Group’s Taysha Gene Therapies TSHA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $603K | Sell |
261,239
-156,893
| -38% | -$362K | ﹤0.01% | 4703 |
|
|
2025
Q1 | $581K | Sell |
418,132
-3,264
| -0.8% | -$4.54K | ﹤0.01% | 4579 |
|
|
2024
Q4 | $729K | Buy |
421,396
+329,395
| +358% | +$570K | ﹤0.01% | 4453 |
|
|
2024
Q3 | $185K | Buy |
92,001
+35,922
| +64% | +$72.2K | ﹤0.01% | 4760 |
|
|
2024
Q2 | $126K | Sell |
56,079
-133,205
| -70% | -$298K | ﹤0.01% | 4881 |
|
|
2024
Q1 | $543K | Buy |
189,284
+185,341
| +4,701% | +$532K | ﹤0.01% | 4033 |
|
|
2023
Q4 | $6.98K | Buy |
3,943
+3,393
| +617% | +$6.01K | ﹤0.01% | 6445 |
|
|
2023
Q3 | $1.74K | Sell |
550
-7,359
| -93% | -$23.3K | ﹤0.01% | 6697 |
|
|
2023
Q2 | $5.23K | Buy |
7,909
+4,359
| +123% | +$2.88K | ﹤0.01% | 6381 |
|
|
2023
Q1 | $2.83K | Sell |
3,550
-198,284
| -98% | -$158K | ﹤0.01% | 7332 |
|
|
2022
Q4 | $456K | Buy |
201,834
+195,562
| +3,118% | +$442K | ﹤0.01% | 3771 |
|
|
2022
Q3 | $12K | Sell |
6,272
-88,288
| -93% | -$169K | ﹤0.01% | 7084 |
|
|
2022
Q2 | $352K | Buy |
94,560
+26,580
| +39% | +$98.9K | ﹤0.01% | 3594 |
|
|
2022
Q1 | $443K | Buy |
67,980
+16,944
| +33% | +$110K | ﹤0.01% | 3837 |
|
|
2021
Q4 | $594K | Buy |
51,036
+17,653
| +53% | +$205K | ﹤0.01% | 3844 |
|
|
2021
Q3 | $622K | Buy |
33,383
+28,083
| +530% | +$523K | ﹤0.01% | 3584 |
|
|
2021
Q2 | $112K | Sell |
5,300
-30,911
| -85% | -$653K | ﹤0.01% | 4761 |
|
|
2021
Q1 | $735K | Buy |
36,211
+462
| +1% | +$9.38K | ﹤0.01% | 3624 |
|
|
2020
Q4 | $949K | Buy |
35,749
+24,749
| +225% | +$657K | ﹤0.01% | 3200 |
|
|
2020
Q3 | $247K | Buy |
+11,000
| New | +$247K | ﹤0.01% | 3869 |
|